Nutritional Growth

Solutions

INVESTOR PRESENTATION

SEPTEMBER 2020

These presentation materials (the Presentation Materials) are confidential and have been prepared by Nutritional Growth Solut ions

(Company). By receiving the Presentation Materials, you acknowledge and represent to the Company that you have read, understood

and accepted the terms of this disclaimer. It is the responsibility of all recipients of these Presentation Materials to obtain all necessary

approvals to receive these Presentation Materials and receipt of the Presentation Materials will be taken by the Company to constitute

a representation and warranty that all relevant approvals have been obtained.

NOT AN OFFER

These Presentation Materials are for information purposes only. The Presentation Materials do not comprise a prospectus, product

disclosure statement or other offering document under Australian law (and will not be lodged with the Australian Securities and

Investments Commission) or any other law. The Presentation Materials also do not constitute or form part of any invitation, offer for

sale or subscription or any solicitation for any offer to buy or subscribe for any securities nor shall they or any part of them form the

basis of or be relied upon in connection therewith or act as any inducement to enter into any contract or commitment with respect to

securities. In particular, these Presentation Materials do not constitute an offer to sell or a solicitation to buy, securities in the United

States of America.

NOT INVESTMENT ADVICE

The Presentation Materials are not investment or financial product advice (nor tax, accounting or legal advice) and are not intended to

be used for the basis of making an investment decision. Recipients should obtain their own advice before making any investment

decision.

SUMMARY INFORMATION

The Presentation Materials do not purport to be all inclusive or to contain all information about the Company or any of the assets,

current or future, of the Company.

The Presentation Materials contain summary information about the Company and its activities which is current as at the date of the

Presentation Materials. The information in the Presentation Materials is of a general nature and does not purport to contain all the

information which a prospective investor may require in evaluating a possible investment in the Company or that would be required in a

prospectus or product disclosure statement or other offering document prepared in accordance with the requirements of Australian law

or the laws of any other jurisdiction, including the United States of America.

The Company does not undertake to provide any additional or updated information whether as a result of new information, future

events or results or otherwise.

FORWARD LOOKING STATEMENTS

Certain statements contained in the Presentation Materials, including information as to the future financial or operating performance of

the Company and its projects, are forward looking statements. Such forward looking statements:

• are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are

inherently subject to significant technical, business, economic, competitive, political and social uncertainties and contingencies;

• involve known and unknown risks and uncertainties that could cause actual events or results to differ materially from estimated or

anticipated events or results reflected in such forward looking statements; and

• may include, among other things, statements regarding estimates and assumptions in respect of prices, costs, results and capital

expenditure, and are or may be based on assumptions and estimates related to future technical, economic, market, political, social

and other conditions.

The Company disclaims any intent or obligation to publicly update any forward looking statements, whether as a result of new

information, future events or results or otherwise.

The words “believe”, “expect”, “anticipate”, “indicate”, “contemplate”, “target”, “plan”, “intends”, “continue”, “budget”, “estimate”, “may”,

“will”, “schedule” and similar expressions identify forward looking statements.

All forward looking statements contained in the Presentation Materials are qualified by the foregoing cautionary statements. Recipients

are cautioned that forward looking statements are not guarantees of future performance and accordingly recipients are cautioned not to

put undue reliance on forward looking statements due to the inherent uncertainty therein.

NO LIABILITY

The Company has prepared the Presentation Materials based on information available to it at the time of preparation. No

representation or warranty, express or implied, is made as to the fairness, accuracy or completeness of the information, opinions and

conclusions contained in the Presentation Materials. To the maximum extent permitted by law, the Company, its related bodies

corporate and the officers, directors, employees, advisers and agents of those entities do not accept any responsibility or liability

including, without limitation, any liability arising from fault or negligence on the part of any person, for any loss arising from the use of

the Presentation Materials or its contents or otherwise arising in connection with it.

CONFIDENTIAL

The contents of these Presentation Materials are confidential. These Presentation Materials are being provided to you on the condition

that you do not reproduce or communicate them or disclose them to, or discuss them with, any other person without the prior written

consent of the Company.

2

Disclaimer

3

Creating Scientifically Formulated Nutritional Shakes and Snacks with Functional Benefits to Help Kids

Let’s Grow Together

4

Investment Highlights

Unique, scientifically formulated nutritional products developed over

twenty years by leading pediatric specialists from world renowned

Schneider Children’s Medical Center in Israel

In market, patented, clinically tested formulas with proven results

benefiting children’s growth

Targeting large growth markets – namely US and China where there is a

clear unmet need for a nutritional solution

Established distribution channels through select in country partners with

proven distribution networks supplemented by direct online sales to

customers

New range of products currently in clinical studies set to significantly

expand the market opportunity in 2021

Healthy Height is coded for insurance coverage in the United States

and is not bound by the same strict regulatory requirements of infant

formula products in China

[VALUE]

9.6%

5.9%

5.2%

7.4%

57.0%

Mor Research Applications Ltd

Ms Hadassa Bymel

Prof. Phillip Moshe

Prof. Raanan Shamir

Other Management

Other Shareholders

5

Transaction Overview

The Offer Details Important dates*

Minimum Subscription

(A$6M)

Maximum

Subscription (A$7M)

Offer price per Share A$0.20 A$0.20

Shares on issue before the Offer 36,500,000 36,500,000

Shares to be issued to the Noteholders 23,214,298 23,214,298

Shares available under the Offer 30,000,000 35,000,000

Total number of Shares on issue at completion of the Offer 89,714,298 94,714,298

Market capitalization of the company at the Offer price (undiluted) A$17,942,860 A$18,942,860

Gross proceeds from the Offer A$6,000,000 A$7,000,000

Enterprise value of the company at the Offer price A$11,942,860 A$11,942,860

Total number of options at completion of the Offer** 32,300,002 32,300,002

Indicative market capitalization of the Company at the Offer price (fully

diluted)

A$24,402,860 A$25,402,860

Shareholders post-IPO

Key Dates

Lodgement of Prospectus 14 September 2020

Opening Date of Offer 23 September 2020

Closing Date of Offer 13 October 2020

Expected Allotment Date of Shares 19 October 2020

Shares expected to trade on ASX (on a normal settlement

basis) 26 October 2020

* Notes: This timetable is indicative only. Unless otherwise indicated, all times given are Australian Eastern Standard Time. The Company, in consultation with the Lead Manager, reserves the right to vary any and all of the above dates without notice (including, subject to the ASX Listing Rules and the

Corporations Act, to close the Offer early, to extend the Closing Date, or to accept late Applications or bids, either generally or in particular cases, or to cancel or withdraw the Offer before Completion of the Offer, in each case without notifying any recipient of this Prospectus or Applicants). If an Offer is

cancelled or withdrawn before Completion of the Offer, then all Application Monies will be refunded in full (without interest) as soon as possible in accordance with the requirements of the Corporations Act. Investors are encouraged to submit their Applications as soon as possible after an Offer opens.

** Performance Options, Performance Rights, Replacement Options and Lead Manager Options to be issued.

Item

Amount

(Minimum Subscription)

Amount

(Maximum Subscription)

Sales & Marketing

Medical education

Marketing and branding

Teen Growth launch

Sports Formula launch

A$2,900,000 A$3,700,000

IP Protection A$100,000 A$100,000

International Expansion & Business Development A$500,000 A$700,000

Research & Development A$500,000 A$500,000

General Administration and Working Capital A$1,000,000 A$1,000,000

Costs of the Offer A$1,000,000 A$1,000,000

Total A$6,000,000 A$7,000,000

6

Use of Funds

The above table is a statement of current intentions as of the date of this Prospectus and excludes any income from existing ongoing sales revenue. As with any budget, intervening events (including commercialisation success or failure) and new circumstances have the potential to affect the manner in

which the funds are ultimately applied. The Board reserves the right to alter the way funds are applied on this basis. The Board believes that funds raised from the Offer, together with existing cash reserves, will provide the Company with sufficient working capital to carry out its stated objectives.

7

Revenue from online

sales selling Healthy

Height to the US via

Amazon and Shopify

have generated circa

AU$1.71M (US$1.18M) in

Calendar Year 2019

Continuous YoY Growth

$0

$100,000

$200,000

$300,000

$400,000

$500,000

$600,000

$700,000

$800,000

$900,000

Q1/18 Q2/18 Q3/18 Q4/18 Q1/19 Q2/19 Q3/19 Q4/19 Q1/20 Q2/20

Sales by quarters AU$

8

Low CAC with Strong LTS

Cost of customer acquisition is

down from US$50 to US$20

Lifetime Sales over US$200 for our

core customer

Average Lifetime Sales are over

US$100

0 50 100 150 200 250 300

Unknown

26-50

Under 10

51+

11-25

$0

$10

$20

$30

$40

$50

$60

Oct-

18

Dec-1

8

Feb-1

9

Apr-

19

Jun-1

9

Aug-1

9

Oct-

19

Dec-1

9

Feb-2

0

Apr-

20

Jun-2

0

CA

C

Month US$

0

20

40

60

80

100

120

140

Mar-

18

Apr-

18

May-

18

Jun-1

8

Jul-18

Aug-1

8

Sep-1

8

Oct-

18

Nov-1

8

Dec-1

8

Jan-1

9

Feb-1

9

Mar-

19

Apr-

19

May-

19

Customer First Order Month

LT

S

• Pediatric protein supplements are a product

category linked to Infant Formula, Foods for

Special Medical Purposes (FSMP) and

Nutritional Growth supplements

• The overall market for these supplements

continues to grow particularly in developing

markets due rising preventative health

measures, a growing awareness of pediatric

nutrition, rising income levels and

reimbursement programs in some markets

• New products are set to significantly expand the

market opportunity for NGS beyond the

pediatric protein supplements

9

The Market

Categories of Nutritional Products

Market sizes

Source: Frost & Sullivan

Infant Formula

~$75bn

FSMP

~$14bn

Nutritional supplements

$140bn

Pediatric protein supplements

Children’s height

is a major concern for

parents around the

world …

10

• Founded by a pediatric endocrinologist and a

pediatric gastroenterologist from Schneider

Children’s Medical Center of Israel who

identified children weren’t growing to their full

potential due to lack of key nutrients

• Unmet need for high-quality nutritional products

scientifically formulated to meet growing

children’s specific nutritional requirements

• We leverage decades of medical expertise to

develop clinically tested shakes and snacks to

help children grow better

11

Our #1 Goal is to Help Kids Grow in Confidence

Our Research

12

Over 20 years

of research on the interaction between

nutrition and growth

Dozens of

published articles

by our team of leading pediatricians

13

Our first product,

Healthy Height, was

designed to include the

nutrients that are most

important for height

gain

With added L-Arginine as a free amino acid

*L-arginine is known to stimulate growth hormone secretion

The Formula

25% Healthy Fats

47% Carbohydrates, specific vitamins &

minerals that are known to have an

effect on growth

28% Protein

(whey protein)

14

The Evidence - Healthy Height Clinical Study

0

0.05

0.1

0.15

0.2

0.25

0.3

0.35

Baseline End of blinded - Phase (0-6m)

End of Extantion - Phase (6-12m)

Formula good Placebo good

P<.00

1 P<.00

1

Prospective, randomized, double-blind,

placebo controlled study (n=200)

The children who received Healthy Height grew better than

the children who received the placebo

They gained height and weight, without an increase in

BMI, showing that growth was proportional, not obesogenic

*Journal of Pediatrics, Labenthal et al, 2014; Yackobovitch-Gavan et al, 2016

Children who consumed Healthy Height grew 13.8%-34% better than the children in the

placebo group

Current Status

• Nutritional Formula:

Commercial Sales

• Protein Bars:

Fully developed (and delicious)

15

In Market - Nutritional Formula to Promote Height in Kids 3-9 Years of Age

• New formula, specifically designed to support

growth of adolescents

• One formula for boys and one formula for girls

since boys and girls have different nutritional

needs during puberty

Current Status

• Product fully developed

• Clinical Study

ETA: Boys Q4 2020, Girls 2021

16

In Development – Junior Growth Formula

• Innovative formula to enhance sports

performance in children and teens

Current Status

• Formula completed

• Clinical study in Israel (soccer) and Slovenia

(swimming)

• ETA: 2020

17

In Development – Formula for Young Athletes

• Pediatric protein supplement market in China is estimated at

US$2.2 billion in 2020 with the CAGR estimated at 9.9% from 2010-20201

18

The China Opportunity

1. Source: Frost & Sullivan

• Demand for clinically proven, reliable, high quality products for

children after the 2008 melamine tainted infant formula crisis –

manufacturing authenticity highly valued by

Chinese consumers

• Road to China market – expanding large-scale distribution

agreements, cross-border sales through e-commerce platforms

Tmall & JD.com, in addition to DaiGou and followed by a retail

distribution program

• NGS products not bound by the same strict regulatory

requirements of infant formula products in China

• Demand for clinically proven, reliable, high quality

products for children with clean label and healthy

ingredients

• Road to US market – expand online distribution through

Amazon and Healthy Height website, reaching out to

healthcare providers, target large scale distribution

agreements through established distributors

• Healthy Height has been assigned an insurance billing

code in the US, which would facilitate the submission of

claims for reimbursement to health insurers.

19

The US Opportunity

Healthy Height

Nutritional Formula

PediaSure Grow &

Gain Nutrition

Powder

Boost Kid

Essentials 1.0

Drink

Orgain Kids

Protein Shakes

Carnation Instant

Breakfast

Company

NGS

(AU$12.6M

pre-money

valuation at listing)

Abbot Laboratories

(US$152BN

company)

Nestle

(US$313BN

company)

Orgain

Private company

(unknown

valuation)

Nestle

(US$313BN

company)

Designed for and clinically-tested in

healthy, short, and lean children in a

prospective, randomized, double-blind,

placebo-controlled trial (PRCT)

Yes No No No No

Contains Corn Syrup No Yes No No No

Protein Per Serving 12 grams 6 grams 7 grams 8 grams 5 grams

Added Sugar Per Serving 9 grams 12 grams 9 grams 13 grams 19 grams

Sodium Per Serving 50 mg 130 mg 140 mg 85 mg 90 mg

Supplemented with L-arginine Yes No No No No

20

Competitor Landscape

21

• New products: Adding new products during 2020-2021, including

Healthy Height for children aged ten and up, Healthy Height protein bar,

and Healthy Height sports

• New sales channels: Establishing new distribution agreements -

selling through retail stores, marketing to healthcare providers and

establishing cross-border ecommerce platforms in China

• New territories: Selling into China, expanding US operations and

targeting South Korea and Europe

• NGS has recently signed a distribution agreement with High Hope

Baby, a Chinese SOE selling the Healthy Height product into

China. Their initial Purchase Order has been placed in January

2020 for US$120,000

Growth Pipeline – Next 18 Months

Roadmap

22

Launch sports

product

Complete teen

formula clinical

study (girls)

Start medical

education campaign Complete teen

formula clinical

study (boys)

Launch Junior

Growth formula +

bars

Complete

sports clinical

study

Start selling in

retail stores

2022 2020 2021 2019

Our management team is comprised of world renowned experts in the field of pediatric, endocrinology and gastroenterology

as well as business executives and deep knowledge of manufacturing and supply chain.

23

Proposed Board of Directors

Brian Leedman

B.Ec, MBA

Non-Executive Chairman

Mr Leedman is a marketing and

investor relations professional with

over 15 years’ experience in the

biotechnology industry. Mr Leedman

was co-founder of ResApp Health,

Oncosil Medical Limited and Biolife

Science Limited (acquired by Imugene

Limited). Mr Leedman was formerly

the WA chairman of AusBiotech, the

association of biotechnology

companies in Australia.

Anton Uvarov

PhD, MBA

Non-Executive Director

Dr. Uvarov is a founding director of

Actinogen Medical and Neuroscientific

Bioharmaceuticals, Australian publicly

listed biotechnology companies. Dr.

Uvarov holds a PhD degree in

Biochemistry and Medical Genetics

from the University of Manitoba,

Canada and an MBA degree from the

University of Calgary, Canada. He is a

former Equities Analyst with Citigroup,

US.

Kinneret Livnat Savitzky, Ph.D

Non-Executive Director

Dr. Kinneret Livnat Savitzky brings to

NGS significant experience in the life

sciences industry, including drug

discovery and development, corporate

partnering and capital raising. Dr.

Livnat Savitzky holds a B.Sc. in

Biology from The Hebrew University of

Jerusalem, and an M.Sc. and Ph.D.

with distinction in Human Genetics

from Tel Aviv University.

Prof. Raanan Shamir

MD

Non-Executive Director / Chief

Medical Officer / Co-Founder

Prof. Shamir is a pediatric

gastroenterologist. He served as

President of ESPGHAN, the European

Society for Pediatric Gastroenterology,

Hepatology and Nutrition.

His current research areas include

pediatric nutrition, nutrition and growth,

celiac disease, inflammatory bowel

disease and childhood hyperlipidemia.

Liron Fendell

L.L.B, MBA

CEO / Managing Director

Liron brings a passion for nutrition,

clinical science, emerging technology

and global child health. Previously a

corporate lawyer in one of Tel Aviv’s

biggest law firms, Liron is a firm

believer in the power of data and in

making data-driven decisions to

increase commercial impact.

Liron has an L.L.B and an MBA from

Tel Aviv University.

Unique, scientifically formulated nutritional products leveraging twenty

years of research

In market, patented, clinically tested formulas with proven results

Targeting large growth markets – namely US and China

Established distribution channels through select in country partners

supplemented by direct online sales to customers

New range of products set to significantly expand the market opportunity in

2020 and 2021

Covered by an insurance billing code in the US, which would facilitate the

submission of claims for reimbursement to health insurers.

NGS products not bound by the same strict regulatory requirements of

infant formula products in China

24

Investment Summary

25

Appendix

26

Company Background

NGS founded in 2013, by two pediatric specialists in

Israel who spent 20+ years investigate the effect of

nutrition on kids’ growth

Current product portfolio includes Healthy Height milk

formula for kids ages 3-9

New products due for release include Healthy Height for

kids 10 years and older along with a sports formula

specifically designed for young athletes in their teens

Currently in market in the US, China and Israel

Healthy Height sold under license in India since 2014

Company is set for large scale commercialisation with

marketing to drive product awareness in key markets

Timeline

27

Expansion

Global

distribution

Recognition

License agreement with GSK

(now Unilever) Introducing

Horlicks Growth Plus in India

Conference

First annual Nutrition & Growth

scientific conference founded

by NGS founders

Strategy Build a brand &

manufacturing

capabilities

Sales

USA

Execution

New Products

Healthy Teen

developed and clinical

research begins

Sales

Israel

launch

Study Completed

Healthy Height clinical

study completed

Research

20+ years of basic

research of nutrition

& growth

Clinical Study

Healthy Height

clinical study

begins

Company

Company founded

to commercialise

the IP

2019 2017 2016 2015 2012 2010 1990’s 2014

Healthy Height (ages 3-9)

• Patent granted (USA, Australia, Israel)

• Pending patent applications in Canada, India, and EU

Junior Formula (ages 9-up)

• Patent granted (USA)

• Pending patent applications in China, India and the EU

Sports Formula

• Under US provisional patent application

28

Patents

29

Executive Team

Prof. Moshe Phillip, MD Prof. Raanan Shamir, MD Pini Ben Elazar Liron Fendell , L.L.B, MBA

Chief Scientific Officer

Prof. Phillip is a Pediatric Endocrinologist. He is

active in both clinical and basic research

focusing on growth, the epiphyseal growth

plate, nutrition, obesity, and childhood diabetes.

Before co-founding NGS, Prof. Phillip founded

Dreamed Diabetes, which later sold to

Medtronic.

Chief Medical Officer

Prof. Shamir is a Pediatric Gastroenterologist.

He served as President of ESPGHAN, the

European Society for Pediatric

Gastroenterology, Hepatology and Nutrition.

His current research areas include pediatric

nutrition, nutrition and growth, celiac disease,

inflammatory bowel disease and childhood

hyperlipidemia.

Director, NGS IL

Pini is the NGS IL board representative for Mor

Research and is actively involved in the

strategic direction of NGS.

Prior to joining Mor Research, Pini founded Bio-

Gal, which he led the start-up up to the

successful merger with XTL (NASDAQ: XTLB).

Before that he was the CEO of On medical

centers, a chain of clinics that treats ED where

he opened 70 clinics in 17 countries, employing

400 physicians. Pini holds an MBA degree from

Johnson & Wales University, Providence

Rhode Island.

CEO / Managing Director

Liron brings a passion for nutrition, clinical

science, emerging technology and global child

health. Previously a corporate lawyer in one of

Tel Aviv’s biggest law firms, Liron is a firm

believer in the power of data and in making

data-driven decisions to increase commercial

impact.

Liron has an L.L.B and an MBA from Tel Aviv

University.

Director, NGS IL; Operations Strategy

Hadassa is a community pharmacist with many years of

experience in developing and researching nutritional

supplements. Being one of the original founders of NGS,

Hadassa is also the CEO of a manufacturing firm which

specialises in nutritional enrichment powders.

Hadassa is responsible for ensuring that the Company's

global manufacturing network is positioned to be a source of

competitive advantage and manages the Company's

Manufacturing strategic planning processes / projects.

Director of Clinical Research

Michal holds Ph.D. in Nutritional sciences from the Hebrew

University of Jerusalem, Israel, and M.Sc. in Biostatistics

from the Tel-Aviv University, Israel.

As Director of Clinical Research, Michal leads the design and

execution of research studies to validate the benefits of using

NGS’ products. Michal works collaboratively with our team

and scientific and clinical advisors to strategise research

projects. Michal applies creative problem solving to inform

how NGS can most effectively and efficiently demonstrate

improved engagement, clinical outcomes, and cost savings

through publishing peer-reviewed articles.

30

Executive Team continued

Hadassa Bymel Michal Yackobovitch-Gavan, Ph.D Jason Zinn

President, North America

Jason Zinn’s career bringing medical and health solutions to

consumers is key as he manages all facets of US operations

including product development, sourcing, marketing strategy

and business development.

He is driven to make a difference in children’s lives by helping

them reach their full potential.

Shares M

Current Shares on issues (NGS Vendors) 40.0 40.0

PRE IPO @14c (A$1.5M) 10.71 10.71

Facilitation Shares 12.5 12.5

IPO Capital Raising (A$5M - A$7M) @20c 25.0 35.0

Total 88.21 98.21

Market Cap on Listing $17.6 $19.6

EV before cost on listing $12.6 $12.6

*One meaningful performance milestones as per below

1. US$3.9M Revenue on consolidated basis 8.8 8.8

*20M unlisted options with a strike price of 20 cents and 5 year expiry from listing

31

Proposed Capital Structure

Nutritional Growth Solutions Grow with Confidence

Liron Fendell

NGS CEO / Managing Director

liron@ngsolutions.co

Tel: +972 52 833 07 90

32